Compound high-throughput screening and activity detection method based on thin-layer chromatography

By combining target proteins and expanding agents by thin layer chromatography, the lack of sensitivity of the high-throughput screening methods in the prior art and the fluorescence interference of the compound in the fluorescence of the compound is solved, and rapid and economical compound screening and verification are achieved, and the screening of signs of compounds is improved. Accuracy and reliability of biological activity verification.

CN119064523AActive Publication Date: 2024-12-03SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202310649967.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03
Estimated Expiration
2043-06-02

AI Technical Summary

Technical Problem

The existing high-throughput screening methods have insufficient sensitivity, low flux and compound fluorescence interference in the screening and activity verification of the lead compound, making it difficult to achieve rapid, economical and efficient compound screening and verification.

Method used

Using a high-throughput screening method based on thin layer chromatography, the compound is mixed by two-step method, combined with the target protein and the developer, the compound position is determined by using the specific shift value, and the polarity and concentration of the compound are detected by thin layer chromatography to verify Its effect on enzyme activity and target protein binding.

Benefits of technology

Fast, economical and efficient compound screening and verification are achieved, avoiding compound fluorescence interference in biochemical experiments, and improving the screening accuracy of the signs of compounds and the reliability of biological activity verification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064523A_ABST
    Figure CN119064523A_ABST
Patent Text Reader

Abstract

The invention relates to a compound high-throughput screening and activity detection method based on thin-layer chromatography. The screening method disclosed by the invention comprises the following operation steps: 1, mixing part of compounds in a compound library in a manner of firstly merging according to rows and then merging according to columns; 2, recycling a seedling compound; 3, backtracking the position of a seedling head compound; the invention further provides a method for verifying the influence of the Miao compound on the enzyme activity reaction process of protease on the basis of thin-layer chromatography and a method for verifying the influence of the Miao compound on the binding of protein and a small molecule substrate or polypeptide on the basis of thin-layer chromatography. The method disclosed by the invention has the characteristics of high efficiency, rapidness, low economic cost and low experimental operation technical threshold.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a high-throughput screening and activity verification method for compounds based on thin-layer chromatography. Background Art

[0002] From lead compounds to lead compounds, to candidate drugs, and finally to clinical application, drug development is an extremely long process. The design and discovery of lead compounds is the starting point of new drug development. According to the screening target, selecting and establishing effective high-throughput methods to capture potential lead compounds from the vast compound library is a key step in opening the road to research and development. And "the most important discovery is the scientific method itself, because it has unlimited potential." At present, a large number of high-throughput screening methods have been developed, and a variety of flexible screening schemes have been derived to meet the needs of compound screening for "more scientific", "more efficient" and "more accurate". In terms of screening objects, compound libraries can be divided into physical compound libraries and virtual compound databases. Correspondingly, small molecule compound high-throughput screening methods can be divided into physical screening and virtual screening. In terms of screening models, high-throughput screening methods can be divided into screening of biological macromolecules such as targeted proteins and nucleic acids and screening based on cell phenotypes. In addition, there is screening using animal models, but compared with the first two, the throughput is lower. Among them, for purified target proteins or nucleic acids, biochemical screening methods and biophysical screening methods are mainly used.

[0003] The objects of biochemical screening methods are usually proteins or nucleic acids, and the targets generally include known substrate molecules, interacting proteins or nucleic acids, etc. According to the specific characteristics of the target, it is a common method to design and synthesize substrate-like probes to detect the inhibition of protein-probe binding by candidate compounds, or to detect the inhibition of target protein activity by compounds. The screening machine has a high sensitivity in detecting light signals such as absorbance, fluorescence intensity, and luminescence intensity. The volume of the reaction system is between 10 and 40 μL, and the amount of protein, compound, and probe is low. 384-well plates are often used as reaction and detection containers, so high-throughput screening is easy to achieve.

[0004] In the screening method of detecting absorbance, the change of system absorbance at a specific absorption wavelength can indicate the consumption of raw materials or the generation of products in the enzyme activity reaction, thereby characterizing the degree of progress of the enzyme activity reaction. The screening method of detecting fluorescence intensity mainly includes total fluorescence intensity analysis and fluorescence ratio method. Among these two methods, the total fluorescence intensity analysis method is easily interfered by the fluorescence generated by the compound to be detected, and the shorter the excitation wavelength of the fluorescent probe, the stronger the interference generated by the compound. Fluorescence ratio methods, such as the commonly used fluorescence anisotropy (FP) and fluorescence resonance energy transfer (FRET), are less interfered by compound fluorescence. The difference between the screening method of detecting luminescence intensity and the method of detecting fluorescence intensity is that the former does not need to provide excitation light, but directly detects the fluorescence emitted by the luciferin in the system after being hydrolyzed by luciferase. This is an irreversible enzyme-catalyzed reaction, so it is impossible to achieve multiple detections of the reaction process like experiments such as FP and FRET.

[0005] Biophysical methods are a series of methods for detecting the interaction between biological macromolecules and small molecule compounds or between biological macromolecules. Unlike biochemical screening methods, biophysical methods are usually used to characterize the binding of proteins and small molecules for the screening of small molecule compounds targeting proteins. Although in certain cases, the effect of small molecules on target activity can be indirectly characterized through clever design, this indirect characterization is still mostly achieved through direct detection of binding. In addition, in practical applications, most biophysical methods do not require the design of corresponding probes like biochemical methods. The reaction system often has only two main components: protein and compound. In some methods, proteins are labeled with dyes to achieve signal visualization.

[0006] Commonly used biophysical methods include surface plasmon resonance (SPR), protein thermal shift (PTS), microscale thermophoresis (MST), isothermal titration calorimetry (ITC), nuclear magnetic resonance (NMR), mass spectrometry (MS), etc. Among them, isothermal titration calorimetry is considered to be the "gold standard" for identifying binding. Compared with biochemical methods, general biophysical methods take a long time to detect a single sample, and most of them are difficult to achieve high-throughput detection. In recent years, based on classical biophysical detection methods, some high-throughput screening methods for compounds have also been developed, such as affinity-selection mass spectrometry (AS-MS) that relies on mass spectrometry detection.

[0007] In general, in the screening and verification of lead compounds, we usually rely on the technical principles of classical experiments, combined with the structural and functional characteristics of specific targets, to rationally design the corresponding screening scheme. Often, multiple methods are used to complement each other, combining biochemical methods with biophysical methods to comprehensively confirm the activity of lead compounds, clarify their mechanism of action, and provide reliable data support for subsequent design modification and in-depth research.

[0008] Thin-layer chromatography (TLC) is a method in which a stationary phase is coated on a plate, and the different adsorption capacities of the components of the sample to be detected on the stationary phase are utilized. When the mobile phase flows through the surface of the stationary phase, the sample components undergo different degrees of adsorption-dissociation-adsorption process, thereby achieving separation. The earliest application record of thin-layer chromatography can be traced back to 1938. After nearly ninety years of development, it is still a widely used separation and identification method. Common stationary phase materials include silica gel, alumina, polyamide, cellulose, and dextran gel. Different stationary phases are combined with corresponding mobile phases to identify different types of samples. Thin layer adsorption chromatography with adsorbent silica gel and alumina as stationary phases is currently the most commonly used thin layer chromatography method.

[0009] In recent years, many derivative methods have been developed based on the theory of classical thin layer chromatography. High performance thin layer chromatography (HPTLC) uses gel particles with a smaller diameter (4-6 μm) as the stationary phase, which increases the number of interactions with the analyte molecules and achieves better separation effects. Ultrathin layer chromatography (UTLC) uses a thinner stationary phase (10 μm) to reduce the lateral diffusion of the analyte. Pressurized thin layer chromatography (OPLC) uses a liquid chromatography (LC) pump to drive the mobile phase through the stationary phase. Microemulsion thin layer chromatography (ME-TLC) uses oil-in-water microemulsion as the mobile phase.

[0010] The relative transfer value Rf is the most important parameter used to determine the properties of the analyte in thin layer chromatography. The relative transfer value = the distance moved by the solute / the distance moved by the developing agent, which is the relative distance that the analyte moves on the stationary phase under the promotion of the developing agent. The substance is subject to two main effects during the development process, the adsorption effect of the stationary phase and the dissolution effect of the mobile phase. Under these two effects, the substance repeatedly adsorbs-dissociates-adsorbs on the surface of the stationary phase. For different substances, these two effects are specific and closely related to their physical / chemical properties, which makes the relative transfer value Rf a characteristic value for the qualitative analysis of compounds.

[0011] By definition, the value of the ratio is between 0 and 1. In the development system, the value of the ratio is mainly determined by three factors: the adsorption strength of the fixed relative compound, the polarity of the compound, and the polarity of the developing agent. In addition, the temperature and humidity of the environment will also affect the development effect. In order to accurately determine the attribution of the analyte, the value of a good development result is generally between 0.2 and 0.8. Usually we achieve this effect by adjusting the polarity of the developing agent.

[0012] Thin layer chromatography color development methods include those that rely on the physical properties of the compound, color development under visible light, ultraviolet light, and fluorescence, and those that rely on chemical properties, using color developers. Color development under 254nm and 365nm ultraviolet light is a broad-spectrum, sensitive and non-destructive color development method, and is generally the preferred color development method. Reducing agents or strong oxidizing agents such as iodine, potassium permanganate solution, and sulfuric acid solution are commonly used broad-spectrum color developers. In addition, some exclusive color developers are used for corresponding compounds with characteristic structures. Under some color development methods, different compounds show different colors, which can be combined with the Rf value to assist in the identification of compounds.

[0013] Thin layer chromatography is often used for qualitative analysis, content determination, separation and purification of compounds. Thin layer chromatography is simple to operate, highly reliable, and sensitive, and is often used as a direct means to monitor the progress of reactions during chemical synthesis. In qualitative analysis, we spot the substance to be detected and its standard in parallel, and develop color when it is developed to the appropriate position. By comparing the relative displacement, we can determine whether the product is generated. By comparing the approximate concentration ratio of the raw material and the product, we can determine the progress of the reaction. For more precise quantification, we need to set a standard concentration gradient, fit a concentration-color intensity standard curve, and calculate the concentration of the substance to be detected by colorimetry. Preparative-grade thin layer chromatography plates can withstand a very high load (500 mg), and the target compound and impurities are separated during the development process. After the development is completed, the stationary phase at the color band of the target compound is scraped off and the product is eluted with an organic reagent.

[0014] The simplicity, speed and economy of thin layer chromatography make it a good method for screening lead compounds, especially for preliminary screening of active ingredients of natural products. Bioautography is the application of thin layer chromatography in the screening of lead compounds. Bioautography is an effect directed analysis (EDA) method that combines chemical analysis with biological detection. In this method, thin layer chromatography is a means of separating compound mixtures, and the thin layer chromatography plate is the carrier of the compound and the place where the biological reaction occurs. Biological materials, such as enzymes or bacteria, are coated on the thin layer chromatography plate carrying the compound, and there is a position where the inhibitory active compound is located, and the enzyme activity reaction or bacterial growth is inhibited. As a result, the enzyme-catalyzed color change reaction cannot be carried out, or the colony cannot be formed, and a color different from the environmental background or a blank is presented at this position.

[0015] In the reported screening methods of one-to-many incubation of proteins and compounds, it is often necessary to introduce special detection methods to determine the information of the lead compound. For example, affinity selection mass spectrometry, bioautoradiography, etc. ultimately rely on mass spectrometers to detect the quality and structure of compounds. In the process of establishing this screening method, we solved the problem of confirming the information of the lead compound by orderly mixing the compounds in the compound library. The compounds in the compound library are usually stored in compound plates of uniform specifications. Each compound has an information record, which is an electronic file of the compound. This electronic file corresponds to the location of the corresponding compound (plate number and well number). Therefore, once the compound position information is determined, the identity of the compound is determined. The operation of orderly mixing compounds allows us to trace the position information of the lead compound, thereby obtaining the electronic file of the compound. Summary of the invention

[0016] The technical purpose of the present invention is to provide a high-throughput screening and activity verification method for compounds based on thin-layer chromatography. The method is convenient, fast, economical and efficient.

[0017] In one aspect, the present invention provides a high-throughput screening method for compounds based on thin layer chromatography, the method comprising:

[0018] 1) Group multiple compounds in the compound library equally. The multiple compound mother solutions are stored in a multi-well plate, with each well storing one compound at a concentration of 1 mM to 10 mM. Mix each group of compounds in the following two steps:

[0019] Step 1.1: Merge by row

[0020] Use a multi-channel gun to take a certain volume from each well in each row of the multi-well plate and merge it into one row; Step 1.2: Merge by column

[0021] Take a certain volume from each well in each column of the compound combined in step 1.1 and combine them into one column.

[0022] After two mergings, each compound mixture obtained contains m*n compounds, wherein m is the number of merged rows, n is the number of merged columns, m is between 8 and 96, and n is between 5 and 10.

[0023] 2) Dilute and mix the target protein and a group of compound mixtures obtained in step 1) with the reaction solution, incubate, and perform desalting operation to separate the protein-compound complex.

[0024] 3). Denaturing the protein using a protein denaturation method to release the lead compound in the complex, and freeze-drying it;

[0025] 4) Detect the lead compound by thin layer chromatography: the freeze-dried sample of step 3) and the m*n compounds obtained in step 1) are dissolved in ethyl acetate and spotted on the same silica gel plate. After the spotting is completed, the ethyl acetate is completely volatilized, and the compounds are developed in sequence with a developing agent until the ratio shift value of the "lead compound" is between 0.2 and 0.8, thereby determining which column of the original compound mother plate the "lead compound" belongs to. Then, the m compounds in the column are dissolved in ethyl acetate and spotted and developed together with the lead compound in sequence until the ratio shift value of the "lead compound" is between 0.2 and 0.8, thereby determining which row of the original compound mother plate the "lead compound" belongs to;

[0026] 5) Determining the information of the hit compound according to the electronic file of the original compound master plate, wherein the electronic file of the original compound master plate is the information corresponding to the position of each compound in the storage container recorded when the compound library is established.

[0027] In a specific embodiment, in step 1), m is 16 and n is 10. Specifically, 160 compounds are mixed by the following "two-step method": 160 compounds correspond to the total amount of compounds in two 96-well plates in the compound library, where each plate has 80 compounds. First, merge by row, use a 10-channel gun to take 1 μL of compound from each well in each row of the two plates, and merge into one row. At this time, there are 16 compounds in each well after merging. Then, merge by column, take 0.5 μL from each well in each column of the compounds obtained in the previous step, and merge into one column. At this time, after two mergers, a mixture of 160 compounds is obtained.

[0028] In a specific embodiment, in step 1), the multiple compounds are dissolved in dimethyl sulfoxide before mixing. After mixing, the dimethyl sulfoxide is removed using a freeze dryer, and a small amount of dimethyl sulfoxide is added to redissolve the compound samples. The volume of dimethyl sulfoxide added when redissolving the compound samples is between 1% and 12% of the total volume of the reaction solution in step 2, preferably 10% based on the tolerance of the target protein to dimethyl sulfoxide.

[0029] In a specific embodiment, in step 2), the target protein may be a protein molecule that is closely related to the occurrence and development of the disease and has drug targeting significance, for example, it may be a full-length or truncated protein expressed by eukaryotic cells or prokaryotic cells.

[0030] In a specific embodiment, in step 2), the target protein working concentration is between 1 and 50 μM, preferably 10 μM. The compound working concentration is between 10 and 100 μM, preferably 50 μM. The total volume of the reaction solution is between 20 and 120 μL, preferably 100 μL.

[0031] In a specific embodiment, in step 2), the reaction solution comprises one or more of 4-hydroxyethylpiperazineethanesulfonic acid buffer (HEPES), tris(hydroxymethylaminomethane) hydrochloric acid (Tris-HCl), 2-morpholineethanesulfonic acid buffer (MES), 3-morpholinepropanesulfonic acid buffer (MOPS), disodium hydrogen phosphate / potassium dihydrogen phosphate buffer, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, EDTA, DTT, Tween-20, NP-40, Triton X-100, bovine serum albumin (BSA), preferably phosphate buffer (1x PBS buffer).

[0032] In a specific embodiment, in step 2), the reaction temperature is between 15 and 45° C., preferably 37° C. The reaction time is between 20 and 60 min, preferably 30 min.

[0033] In a specific embodiment, in step 2), the desalting method is to use Zeba Spin Desalting Columns (Thermo Fisher Scientific #89883) or Zeba Spin Desalting Plate (Thermo Fisher Scientific #89807) for desalting.

[0034] In a specific embodiment, in step 3), the denaturation method is selected from the group consisting of a heating denaturation protein method, an organic reagent extraction compound method, and an organic reagent denaturation protein method, preferably an organic reagent denaturation protein method. The organic reagent may be ethanol, acetonitrile, methanol, dimethyl sulfoxide, etc., more preferably acetonitrile, and the volume of acetonitrile is 2 to 5 times the volume of the reaction solution, preferably 3 times.

[0035] In a specific embodiment, in step 4), the plate used in the thin layer chromatography method is a silica gel plate.

[0036] In a specific embodiment, in step 4), the color development method used in the thin layer chromatography is iodine color development, potassium permanganate solution color development, ultraviolet light color development, preferably ultraviolet light color development.

[0037] In a specific embodiment, in step 4), the developing solvent used in the thin layer chromatography is one or more of petroleum ether, ethyl acetate, dichloromethane, methanol, triethylamine, acetic acid, and water.

[0038] In a specific embodiment, in step 4), the compound is developed in sequence using developing agents from low polarity to high polarity (from 1# to 5#). The preferred developing agent formula (the polarity of developing agents 1# to 5# increases in sequence) is as follows:

[0039]

[0040] In a specific implementation scheme, in step 4), the freeze-dried sample and 10 groups (16 compounds in each group) of 160 compounds after the first round of mixing in step 1 are dissolved in 5 μL of ethyl acetate and spotted on the same silica gel plate. After the spotting is completed, the ethyl acetate is completely evaporated, and the compounds are developed in sequence with 5 polar gradient developing agents (from 1# to 5#) respectively, until the ratio shift value of the "lead compound" is between 0.2 and 0.8, so as to determine which group the "lead compound" belongs to (i.e., to which column of the original compound mother plate the compound belongs). Then, the 16 compounds in the column are dissolved in ethyl acetate and spotted in sequence together with the lead compound, until the ratio shift value of the "lead compound" is between 0.2 and 0.8, so as to determine which group the "lead compound" belongs to (i.e., to which row of the original compound mother plate the compound belongs).

[0041] In a specific embodiment, the information includes, but is not limited to, the CAS number, structure, molecular formula, and relative molecular mass of each compound.

[0042] In another aspect, the present invention provides a method for verifying the effect of a lead compound on the enzymatic activity reaction process of a protease, the method comprising the following steps:

[0043] 2.1: Use the reaction solution to dilute the protease to be tested, the lead compound and the DMSO with the volume corresponding to the mother solution of the lead compound to obtain a protease solution, a lead compound solution and a DMSO solution respectively, and mix the diluted protease solution and the lead compound solution as the experimental group; corresponding to the volume of the experimental group, mix the diluted protease solution and the DMSO solution as the NCC (no compound control) group; corresponding to the volume of the experimental group, mix the blank reaction solution and the diluted DMSO solution as the NPC (no protein control) group;

[0044] 2.2: Add the corresponding substrate diluted with the reaction solution to the mixed solution of the experimental group and the NCC group and the NPC group in step 2.1 to start the catalytic reaction;

[0045] 2.3: heating the solution in step 2.2 to terminate the catalytic reaction;

[0046] 2.4: Analyze the sample taken from step 2.3 by thin layer chromatography. Spot the sample taken from step 2.3 on a silica gel plate, develop it with a developing agent, and observe the difference in substrate consumption / product generation between the experimental group, NCC group, and NPC group to determine the inhibitory / stimulatory effect of the compound on the protease activity.

[0047] In a specific embodiment, the hit compound can be obtained by screening using the method described above.

[0048] In a specific embodiment, in step 2.1, the working concentration of the protease is between 20 nM and 20 μM, the working concentration of the hit compound is between 2 μM and 2 mM, the incubation time is between 20 and 60 min, and the incubation temperature is between 15 and 45°C.

[0049] In a specific embodiment, in step 2.2, the working concentration of the substrate is between 2 and 200 μM, the total volume of the reaction system is between 10 and 100 μL, the incubation time is between 20 and 60 min, and the incubation temperature is between 15 and 45°C.

[0050] In a specific embodiment, the reaction solution in step 2.1 and step 2.2 comprises one or more of 4-hydroxyethylpiperazineethanesulfonic acid buffer (HEPES), tris(hydroxymethylaminomethane) hydrochloric acid (Tris-HCl), 2-morpholineethanesulfonic acid buffer (MES), 3-morpholinepropanesulfonic acid buffer (MOPS), disodium hydrogen phosphate / potassium dihydrogen phosphate buffer, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, EDTA, DTT, Tween-20, NP-40, Triton X-100, bovine serum albumin (BSA), preferably phosphate buffer (1xPBS buffer) and Tris-HCl buffer.

[0051] In a specific embodiment, in step 2.3, the heating temperature is 80-100°C, preferably 100°C, and the heating time is 3-5 min, preferably 3 min.

[0052] In a specific embodiment, the developing agent used in step 2.4 is not particularly limited. For example, the developing agent can be selected from the aforementioned 1# to 5# developing agents of different polarities as described in step 4) above according to the properties of the substance to be developed.

[0053] In another aspect, the present invention provides a method for verifying the effect of a hit compound on the binding of a protein to a small molecule substrate or a polypeptide, the method comprising the following steps:

[0054] 3.1: The protein diluted with the reaction solution and the hit compound are mixed evenly, and incubated for a certain period of time as the experimental group, and a control group is set up at the same time. The difference between the control group and the experimental group is that the hit compound is not contained;

[0055] 3.2: Add the small molecule substrate or polypeptide corresponding to the protein diluted with the reaction solution to the mixed solution of the experimental group and the control group obtained in step 3.1, respectively, and desalt after incubation for a certain period of time;

[0056] 3.3: Denature the protein, take the effluent after desalting, and freeze-dry it;

[0057] 3.4: Analyze the sample in step 3.3 by thin layer chromatography. Redissolve the sample in step 3.3 with solvent and spot it on the silica gel plate. Develop it with a developing agent and observe the changes in the recovery amount of substrate / peptide in the experimental group and the control group to determine the effect of the compound on the binding of protein with small molecule substrate or peptide.

[0058] In a specific embodiment, the hit compound can be obtained by screening using the method described above.

[0059] In a specific embodiment, in step 3.1, the working concentration of the protein is between 20 nM and 20 μM, the working concentration of the hit compound is between 2 μM and 2 mM, the incubation time is between 20 and 60 min, and the incubation temperature is between 15 and 45°C.

[0060] In a specific embodiment, the reaction solution in step 3.1 and step 3.2 comprises one or more of 4-hydroxyethylpiperazineethanesulfonic acid buffer (HEPES), tris(hydroxymethylaminomethane) hydrochloric acid (Tris-HCl), 2-morpholineethanesulfonic acid buffer (MES), 3-morpholinepropanesulfonic acid buffer (MOPS), disodium hydrogen phosphate / potassium dihydrogen phosphate buffer, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, EDTA, DTT, Tween-20, NP-40, Triton X-100, bovine serum albumin (BSA), preferably phosphate buffer (1x PBS buffer).

[0061] In a specific embodiment, in step 3.1, the total volume of the reaction solution is between 20 and 120 μL, preferably 100 μL.

[0062] In a specific embodiment, in step 3.2, the concentration of the small molecule substrate / polypeptide is between 10 and 200 μM, the incubation time is between 20 and 60 min, and the incubation temperature is between 15 and 45°C.

[0063] In a specific embodiment, in step 3.3, the protein denaturation method is selected from the group consisting of heating denaturation protein method, organic reagent extraction compound method, and organic reagent denaturation protein method, preferably organic reagent denaturation protein method. The organic reagent can be ethanol, acetonitrile, methanol, dimethyl sulfoxide, etc., more preferably acetonitrile.

[0064] In a specific embodiment, the solvent used in step 3.4 includes but is not limited to water, ethyl acetate, dichloromethane, etc., and the volume is 5 to 10 μL.

[0065] In a specific embodiment, the developing agent used in step 3.4 is not particularly limited. For example, the developing agent may be the same as described in step 4) above. Depending on the properties of the substance to be developed, developing agents of different polarities from 1# to 5# may be selected.

[0066] Beneficial Effects

[0067] The present invention provides a method for high-throughput screening of lead compounds from mixed compounds by separating and visualizing compounds with the help of thin-layer chromatography. The two-step method used in the screening method of the present invention is characterized by high efficiency, low economic cost, and low technical threshold for experimental operation.

[0068] Furthermore, by separating and visualizing enzyme substrates / products with thin layer chromatography, a method for indicating the effect of compounds on enzyme activity / enzyme activity reaction process is provided; by separating and visualizing target protein small molecule substrates / peptides with thin layer chromatography, a method for verifying the effect of compounds on the binding of target proteins with substrates / peptides is also provided. The provision of these methods can further confirm the exact biological activity of the lead compounds screened by the above screening methods. The verification method of the present application can exclude false positive lead compounds that do not affect the biological activity of the target protein; it can effectively separate compounds and substrates, avoiding the problem of fluorescence interference of compounds that may be caused by detecting all components of the system together in biochemical experiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0069] Figure 1 : Schematic diagram of the principle of high-throughput screening of compounds based on thin layer chromatography.

[0070] Figure 2 : Schematic diagram of the operating process of the "two-step method" for mixing 160 compounds in this application.

[0071] Figure 3 :Schematic diagram of the process of determining the location information of lead compounds in the high-throughput screening method of compounds based on thin layer chromatography.

[0072] Figure 4 : Results of high-throughput screening of compounds targeting BPTF.

[0073] Figure 5 : Results of high-throughput screening of compounds targeting USP7.

[0074] Figure 6 : Experimental results of inhibition of USP7 enzyme activity by the positive compound GNE-6776 based on thin layer chromatography.

[0075] Figure 7 :The experimental results of verifying the inhibition of OGT enzyme activity by compounds based on thin layer chromatography.

[0076] Figure 8 :The experimental results of verifying the inhibition of OGT binding with substrate by positive compounds based on thin layer chromatography.

[0077] Fig. 9 :The experimental results of verifying the inhibition of OGT binding to polypeptide by positive compounds based on thin layer chromatography. DETAILED DESCRIPTION

[0078] The following examples will further illustrate the present invention, but are not intended to limit the scope of the present invention.

[0079] Example 1: High-throughput screening of compounds targeting BPTF

[0080] BPTF (bromodomain PHD finger transcription factor) protein was used to recover the hit compounds from the mixed compounds, and the original position of the hit compounds in the compound library was determined by thin layer chromatography.

[0081] (1) Materials:

[0082] GST-BPTF (2914-3037) protein, 96-well plate (Thermo Fisher Scientific #249944), Zeba Spin Desalting Plate (Thermo Fisher Scientific #89807), PBS buffer (Meilun #MA0015), centrifuge (Eppendorf, 5417R), freeze dryer (Alpha 3-4LSC basic), ethyl acetate (Sinopharm #10009418), methanol (Sinopharm #10014159), petroleum ether (Sinopharm #10015218), dichloromethane (Sinopharm #80047318), thin layer chromatography silica gel plate (J&K #956419).

[0083] (2) Operation steps:

[0084] ① Mixed compounds: 4800 compounds correspond to the compound library (the compounds in this application are all purchased from Topscience and constitute a compound library with a capacity of 4800. It should be noted that the compound library is not restrictive in this application. As long as the compound information is available, technicians in this field can obtain a compound library of any capacity.) The total amount of compounds in 60 96-well plates (80 compounds per plate), 160 compounds in every two plates are finally mixed into one group. First, merge by row, use a 10-channel pipette to take 1 μL of compound from each well in each row of the two plates, merge into one row, and mix thoroughly. At this point, there are 16 compounds in each merged well. Then, merge by column, take 0.5 μL from each well in each column of the compounds obtained in the previous step, and merge into one column. At this point, after two merges, 30 groups of mixtures of 160 compounds in each group are obtained. The samples merged twice were freeze-dried separately to remove the DMSO (dimethyl sulfoxide) solvent.

[0085] ② Recover the lead compound: Redissolve the freeze-dried 160 compound mixed samples with 10μL DMSO, and add 40μL 1x PBS to dilute the compound. The compound concentration is 100μM. Dilute BPTF protein to 20μM with PBS. Mix the compound and protein solution (50μL+50μL) in equal volumes, set up the NCC group (10μL DMSO+40μL PBS+50μL protein solution), and incubate at room temperature for 30min. After incubation, centrifuge at 4℃, 13000rpm for 10min. Desalt the supernatant with ZebaSpin Desalting Plate. Add 3 times the volume of acetonitrile denatured protein to the effluent, centrifuge at 25℃, 13000rpm for 10min, remove the protein precipitate, and freeze-dry the supernatant.

[0086] ③Retrace the position of the "lead compound": Dissolve the freeze-dried sample and the 10 groups of 160 compounds in the first round of mixing in the "mixed compound" step with 5μL ethyl acetate and spot them on the same silica gel plate. After the spotting is completed, wait for the ethyl acetate to completely evaporate, and use the 5 polar gradient developing agents (from 1# to 5#) mentioned above to develop the compounds in sequence until the ratio of the "lead compound" is between 0.2 and 0.8. This determines which group the "lead compound" belongs to (that is, determines which column of the original compound mother plate the compound belongs to). Dissolve the freeze-dried sample and the 16 compound standards in the column with 5μL ethyl acetate and spot them on the same silica gel plate. After the spotting is completed, wait for the ethyl acetate to completely evaporate, and use the 5 polar gradient developing agents to develop the compounds in sequence until the ratio of the "lead compound" is between 0.2 and 0.8. This determines which group the "lead compound" belongs to (that is, determines which row of the original compound mother plate the compound belongs to).

[0087] (3) Experimental results analysis

[0088] This screening method determines the structural information of the lead compound through its position, and the two-step method effectively ensures the convenience and order when tracing back the position of the compound. The basic screening unit of 160 compounds just corresponds to the total number of compounds in the two 96-well plates in the compound library. Relying on the correspondence between the layout of instruments and consumables (multi-channel pipettes, 96-well compound plates, and 96 pipette tips per box), this method adopts a mixed strategy of "merging rows first, then merging columns". Conversely, when determining the position of the lead compound, the analysis method of "determining the number of columns first, then determining the number of rows" is adopted. Figure 4As shown, taking compound 02-H06 (CAS No.: 2758411-46-8) as an example, through the above method, the first step is to determine that the lead compound comes from the 6th column, and the second step is to determine that the compound belongs to the Hth row of compound plate No. 2. The position of the lead compound is accurately determined to be 02-H06 among the 160 compounds, and then the corresponding lead compound structure information is queried from the compound library information table according to its position.

[0089] Example 2: High-throughput screening of compounds targeting USP7

[0090] USP7 protein was used to recover the hit compounds from the mixed compounds, and the original position of the hit compounds in the compound library was determined by thin layer chromatography.

[0091] (1) Materials:

[0092] His-USP7 (208-560) protein, 96-well plate (Thermo Fisher Scientific #249944), Zeba Spin Desalting Plate (Thermo Fisher Scientific #89807), PBS buffer (Meilun #MA0015), centrifuge (Eppendorf, 5417R), freeze dryer (Alpha3-4LSC basic), ethyl acetate (Sinopharm #10009418), methanol (Sinopharm #10014159), petroleum ether (Sinopharm #10015218), dichloromethane (Sinopharm #80047318), thin layer chromatography silica gel plate (J&K #956419).

[0093] (2) Operation steps

[0094] ① Mixed compounds: Every 160 compounds in 4800 compounds (the corresponding compounds and compound libraries are the same as in Example 1) are finally mixed into a group. First, merge by row, use a 10-channel pipette to take 1 μL of compound from each well in each row of the two plates, merge into a row, and mix thoroughly. At this point, there are 16 compounds in each merged well. Then, merge by column, take 0.5 μL from each well in each column of the compounds obtained in the previous step, and merge into one column. At this point, after two merges, 30 groups of mixtures of 160 compounds in each group are obtained. Freeze-dry the samples merged twice to remove the DMSO solvent.

[0095] ② Recover the lead compound: Redissolve the freeze-dried 160 compound mixed samples with 10μL DMSO, and add 40μL 1x PBS to dilute the compound. The compound concentration is 100μM. Dilute USP7 protein to 20μM with PBS. Mix the compound and protein solution (50μL+50μL) in equal volumes, set up the NCC group (10μL DMSO+40μL PBS+50μL protein solution), and incubate at room temperature for 30min. After incubation, centrifuge at 4℃, 13000rpm for 10min. Desalt the supernatant with ZebaSpin Desalting Plate. Add 3 times the volume of acetonitrile denatured protein to the effluent, centrifuge at 25℃, 13000rpm for 10min, remove the protein precipitate, and freeze-dry the supernatant.

[0096] ③Retrace the position of the "lead compound": Dissolve the freeze-dried sample and the 10 groups of 160 compounds in the first round of mixing in the "mixed compound" step with 5μL ethyl acetate and spot them on the same silica gel plate. After the spotting is completed, wait for the ethyl acetate to completely evaporate, and use the 5 polar gradient developing agents (from 1# to 5#) mentioned above to develop the compounds in sequence until the ratio of the "lead compound" is between 0.2-0.8 to determine which group the "lead compound" belongs to (that is, to determine which column of the original compound mother plate the compound belongs to). Dissolve the freeze-dried sample and the 16 compound standards in the column with 5μL ethyl acetate and spot them on the same silica gel plate. After the spotting is completed, wait for the ethyl acetate to completely evaporate, and use 5 polar gradient developing agents to develop the compounds in sequence until the ratio of the "lead compound" is between 0.2 and 0.8. In this way, it is determined which group the "lead compound" belongs to (that is, to determine which row of the original compound mother plate the compound belongs to).

[0097] (3) Experimental results analysis

[0098] like Figure 5 As shown in the figure, taking compound 158-B10 (5-(5-pyrimidinyl)indoline) as an example, the first step determined that the hit compound belonged to column 10 of the two compound plates 158 and 159. The second step further determined that the compound belonged to row B of plate 158. It can be seen that the original position of the hit compound is 158-B10.

[0099] Example 3: Testing the inhibition of USP7 (ubiquitin-specific protease 7) activity by positive compounds

[0100] The USP7 catalytic products were separated by thin layer chromatography to indicate the progress of the enzyme reaction. The inhibition of the USP7 enzyme activity by the positive compounds was verified by comparing the difference in the amount of hydrolysis products within a fixed time.

[0101] (1) Material preparation:

[0102] His-USP7 (208-560) protein, ubiquitin-rhodamine 110 (Keshengjing peptide), GNE-6776 (MCE#HY-107986), reaction solution (50mM Tis-HCl, pH 7.4, 100mM NaCl, 0.05% CHAPS, 1mM EDTA, pH8.0), Zeba Spin Desalting Plate (Thermo Fisher #89807), centrifuge (Eppendorf, 5417R), freeze dryer (Alpha 3-4LSC basic), ethyl acetate (Sinopharm #10009418), methanol (Sinopharm #10014159), petroleum ether (Sinopharm #10015218), dichloromethane (Sinopharm #80047318), thin layer chromatography silica gel plate (B&K #956419).

[0103] (2) Operation steps

[0104] ① Use a reaction solution containing 4% DMSO to dilute USP7 protein to 400nM, dilute compound GNE-6776 to 800μM, and then dilute to 7 concentrations at a two-fold volume ratio. Mix His-USP7 protein and compound (2.5μL+2.5μL) in equal volumes and incubate at room temperature for 30min as the experimental group. Set up the NCC (no compound control) group (2.5μL reaction solution containing 4% DMSO + 2.5μL His-USP7 protein solution) and the NPC (no protein control) group (2.5μL reaction solution containing 4% DMSO + 2.5μL reaction solution). (It should be noted here that in order to offset the possible impact of the solvent DMSO used in the compound mother solution on the experiment, in the NPC and NCC groups, "DMSO solution obtained by diluting the corresponding volume of DMSO solvent with the reaction solution" was used instead of "diluting the compound mother solution with the reaction solution" in the experimental group.)

[0105] ② Add 5 μL of 2 μM ubiquitin-rhodamine 110 to each solution, at which time the protein concentration is 100 nM and the highest concentration of the compound is 200 μM. The enzyme activity reaction is carried out at 37°C for 1 hour.

[0106] ③ Heat each group of solutions to 100℃ and keep for 3min to terminate the reaction and precipitate the protein. Centrifuge at 25℃, 13000rpm for 10min to remove the precipitate, take each group of supernatant solutions and spot them on the silica gel plate, and evaporate the solvent with an electric heat gun. Develop the sample in 4# developing agent (ethyl acetate: methanol = 3:2). After the developing agent reaches the designated front, take out the silica gel plate, evaporate the developing agent, and observe the color development of each group of rhodamine 110 under ultraviolet light.

[0107] (3) Experimental results analysis

[0108] In this experiment, the amount of rhodamine 110 detected by thin layer chromatography indicated the extent of the enzyme activity reaction, e.g. Figure 6 As shown in the figure, compared with the NCC (no compound control) group, as the compound concentration increased, the amount of rhodamine 110 detected in the corresponding experimental group gradually decreased, indicating that the compound inhibited the deubiquitination hydrolysis activity of USP7. At the same time, the development process of thin layer chromatography separated the compound and rhodamine 110, which is different from the method in which all components of the classic enzyme activity reaction system are detected together, effectively avoiding the interference of the compound's own fluorescence on the detection results.

[0109] Example 4: Testing the inhibition of OGT (O-GlcNAc transferase) activity by positive compounds and hit compounds

[0110] The OGT substrate O-GlcNAc was separated by thin layer chromatography to indicate the progress of the enzyme reaction. The inhibition of the compound on the OGT enzyme activity was verified by comparing the difference in the amount of substrate consumed within a fixed time.

[0111] (1) Materials

[0112] His-OGT (313-1031) protein, reaction solution (50 mM Tris-HCl, pH 7.8, 20 mM CaCl2, 0.05% Tween-20, 0.05% NP-40, 0.1% BSA, 500 μM TCEP), UDP-GlcNAc (Sigma, U4375), OMSI-4 (MCE#HY-114361), centrifuge (Eppendorf, 5417R), freeze dryer (Alpha 3-4LSC basic), ethyl acetate (Sinopharm #10009418), methanol (Sinopharm #10014159), petroleum ether (Sinopharm #10015218), dichloromethane (Sinopharm #80047318), thin layer chromatography silica gel plate (B&K #956419).

[0113] (2) Operation steps

[0114] ① Use 12.5% ​​DMSO reaction solution to dilute OGT protein to 20 μM, dilute compound B (CAS No.: 2645-32-1) and OMSI-4 to 4 mM, dilute polypeptide (SEQ ID No.: 1: STPVSRANMK, with biotin modification) to 200 μM, and dilute UDP-GlcNAc to 200 μM.

[0115] Protein and compound were mixed in equal volumes (2.5 μL + 2.5 μL) and incubated at room temperature for 30 min. NCC (no compound control) group (2.5 μL reaction solution containing 12.5% ​​DMSO + 2.5 μL OGT protein solution) and NPC (no protein control) group (2.5 μL reaction solution containing 12.5% ​​DMSO + 2.5 μL reaction solution) were set up.

[0116] ② Add 2.5 μL of diluted peptide and 2.5 μL of UDP-GlcNAc to each solution. The enzyme activity reaction was carried out at 25°C for 1 hour.

[0117] ③ Heat each group of solutions to 100℃ and keep for 3min to terminate the reaction and precipitate the protein. Centrifuge at 25℃, 13000rpm for 10min to remove the precipitate, take each group of supernatant solutions and spot them on the silica gel plate, and evaporate the solvent with an electric heat gun. Develop the sample in 5# developing agent (dichloromethane: methanol: water = 3:2:0.5). After the developing agent reaches the designated front, take out the silica gel plate, evaporate the developing agent, and observe the color development of each group of UDP-GlcNAc under ultraviolet light.

[0118] (3) Experimental results analysis

[0119] First, by comparing the NCC (no compound control) group and the NPC (no protein control) group ( Figure 7 ), it was found that the compound spot corresponding to UDP-GlcNAc (indicated by the white dotted box) in the NCC group was extremely weak, indicating that the enzyme activity reaction of this group proceeded normally and consumed most of the substrate UDP-GlcNAc. In addition, in addition to the consumption of UDP-GlcNAc, an obvious new band can be seen in the NCC group. According to the OGT reaction principle, it is speculated that the compound corresponding to this band should be UDP (indicated by the white dotted box), one of the products of the OGT enzyme activity reaction. The amount of UDP-GlcNAc in experimental group 1 treated with OMSI-4 and experimental group 2 treated with compound B was equivalent to that in the NPC group, indicating that compound OMSI-4 and compound B effectively inhibited the glycosylation reaction catalyzed by OGT. At the same time, Figure 7As shown, after development, the compound, substrate and product are effectively separated, so that this method does not have the problem of fluorescence interference of the compound that may be caused by detecting all components of the system together as in classical biochemical experiments.

[0120] Example 5: Testing the effects of positive compounds and hit compounds on the binding of OGT to substrate O-GlcNAc.

[0121] The substrate O-GlcNAc is separated by thin layer chromatography, and the difference in the amount of O-GlcNAc recovered is compared to indicate the effect of the compound on the binding of OGT with the substrate O-GlcNAc.

[0122] (1) Material preparation

[0123] His-OGT (313-1031) protein, PBS buffer (Meilun), UDP-GlcNAc (Sigma, U4375), OMSI-4 (MCE#HY-114361), Zeba Spin Desalting Columns (Thermo Fisher #89883), centrifuge (Eppendorf, 5417R), freeze dryer (Alpha 3-4LSC basic), ethyl acetate (Sinopharm #10009418), methanol (Sinopharm #10014159), petroleum ether (Sinopharm #10015218), dichloromethane (Sinopharm #80047318), thin layer chromatography silica gel plate (B&K #956419).

[0124] (2) Operation steps

[0125] ① Add 17.67 μL of 283 μM OGT protein to 100 μL reaction system, and add 1.25 μL of 20 mM compound B (CAS No.: 2645-32-1) (experimental group 1, EG1) and OMSI-4 (experimental group 2, EG2) to make the protein working concentration 50 μM and the compound working concentration 250 μM. After mixing the two evenly, incubate at room temperature for 30 minutes, and set up the NCC group (17.67 μL OGT protein solution + 1.25 μL DMSO + 81.08 μL PBS buffer).

[0126] ②After the incubation, add 0.5 μL of 10 mM UDP-GlcNAc solution (working concentration is 50 μM) to the system, mix well and incubate at room temperature for 30 min. Take 10 μL of the reaction solution from each group as the "input" control. Centrifuge the remaining reaction solution, desalt, denature, and freeze-dry the supernatant.

[0127] ③ Use 10 μL ethyl acetate to redissolve the dried sample, spot the compound B standard (cpd1), experimental group 1 (EG1, components: compound B, OGT, UDP-GlcNAc), OMSI-4 standard (cpd2), experimental group 2 (EG2, components: compound OMSI-4, OGT, UDP-GlcNAc), UDP-GlcNAc standard, and NCC group on the same silica gel plate. First, use the developer corresponding to the substrate UDP-GlcNAc to develop the sample. After development, observe the color development of UDP-GlcNAc in the experimental group under ultraviolet light and take photos to record.

[0128] ④ Develop the sample using the developer corresponding to compound B and OMSI-4. After development, observe the color development of the experimental group compound under ultraviolet light. To show that the initial amount of OGT protein in each group is consistent, add an equal volume of loading buffer to the 10 μL "input" control group sample left in each group, and use polyacrylamide gel electrophoresis to develop the protein sample. After electrophoresis, use Coomassie Brilliant Blue dye to stain.

[0129] (3) Experimental results analysis

[0130] The literature reports that the OGT inhibitor OMSI-4 binds to the same region of OGT as the substrate UDP-GlcNAc, so there is a binding competition with UDP-GlcNAc. As predicted, after the addition of the positive compound OMSI-4, the binding amount of the substrate UDP-GlcNAc decreased, and the compound OMSI-4 ( Figure 8 ). Similarly, the experiment proved that the lead compound B (CAS No.: 2645-32-1) also inhibited the binding of OGT to the substrate UDP-GlcNAc. This is consistent with the principle of classic biochemical experiments - the binding of active compounds to proteins will lead to a decrease in the binding of the corresponding substrate analog fluorescent probe, which in turn leads to a change in the detected fluorescence signal value.

[0131] In this method, there is no need to design synthetic substrate analogs. Thin layer chromatography can directly detect compounds and substrates, and simply determine the binding inhibition / competition of compounds on natural substrates. Figure 8 As shown, by developing twice, the compound and the substrate are effectively separated, avoiding the problem of fluorescence interference caused by the compound when all components of the system are detected together in biochemical experiments.

[0132] Example 6: Detection of OGT binding to polypeptide using thin layer chromatography

[0133] The peptides were separated and visualized using thin layer chromatography, and the difference in the amount of recovered peptides was compared to reflect the binding of OGT to the peptides.

[0134] (1) Materials

[0135] His-OGT (313-1031) protein, peptide (GenScript), PBS buffer (Meilun), centrifuge (Eppendorf, 5417R), Zeba Spin Desalting Columns (Thermo Fisher Scientific #89883), freeze dryer (Alpha 3-4LSCbasic), ethyl acetate (Sinopharm #10009418), methanol (Sinopharm #10014159), petroleum ether (Sinopharm #10015218), dichloromethane (Sinopharm #80047318), iodine (McLean #C13454535), thin layer chromatography silica gel plate (J&K #956419).

[0136] (2) Operation steps

[0137] ① Dilute His-OGT protein to 50μM and peptide (SEQ ID No.: 1: STPVSRANMK, with biotin modification) to 200μM with 1x PBS. Mix protein and peptide in equal volumes (20μL+20μL) as the experimental group. Set up a protein control group, that is, mix PBS and protein in equal volumes (20μL+20μL). Set up a peptide control group, that is, mix PBS and peptide in equal volumes (20μL+20μL). Take out two samples of 5μL each from each of the above groups, one as the "before desalting" sample group, and the other as the "OGT protein input group" (to prove that the amount of protein added in the experimental group, protein control group, and peptide control group is accurate), and incubate the remaining 30μL solution at room temperature for 20min.

[0138] ② Use 1x PBS solution to balance Zeba Spin Desalting Columns. Add 300μL 1x PBS solution to the desalting column, centrifuge at 4°C, 1000g for 1min in a centrifuge, discard the effluent, and repeat four times. Add 30μL of the sample solution from each group after incubation to the desalting column balanced with 1x PBS, centrifuge at 4°C, 1000g for 1min in a centrifuge, and discard the desalting column. Heat the effluent from each group to 100°C in a metal bath and keep it for 3min to fully denature and precipitate. Centrifuge the protein-denatured solution in a centrifuge at 4°C, 13000rpm for 10min, and take the supernatant.

[0139] ③ The obtained supernatant was spotted on the silica gel plate with a pipette, and the spotting volume was 0.5 μL each time. After each spotting, the solvent (water) was blown dry with an electric heat gun, and the spotting was repeated, with a total loading volume of 2.5 μL. The sample was developed using 5# developing agent (dichloromethane: methanol: water = 3:2:0.5). After the development was completed, the developing agent was blown dry, and the silica gel plate was immersed in iodine-silica gel powder for 10 seconds and then taken out to observe the color development. The "before desalting" sample followed the same steps as above, and the supernatant was taken after the protein was denatured to complete the thin layer chromatography experiment. The "OGT protein input group" sample was added with an equal volume of loading buffer, and the SDS-PAGE experiment was completed and stained with Coomassie Brilliant Blue staining solution.

[0140] (3) Experimental results analysis

[0141] like Fig. 9 As shown, before desalting, both the "experimental group" and the "peptide control group" had obvious bands corresponding to the peptides, and the color development was comparable, indicating that the amount of peptide added to the two groups was comparable. Due to the presence of protein-peptide complexes, after the desalting step, the retention of the peptides in the "experimental group" was significantly greater than that in the "peptide control group", providing sufficient detection windows to verify the effects of compounds on the binding of proteins to peptides. Using thin layer chromatography for detection, there is no need to design and synthesize peptides with labels or fluorescent probes. Peptides can generally be colored using iodine or potassium permanganate solutions, saving costs and reducing experimental limitations.

Claims

1. A high-throughput screening method for compounds based on thin layer chromatography, the method comprising: 1) Group multiple compounds in the compound library equally. The multiple compound mother solutions are stored in a multi-well plate, with each well storing one compound at a concentration of 1 mM to 10 mM. Mix each group of compounds in the following two steps: Step 1.1: Merge by row A multi-channel row gun is used to take a certain volume from each well in each row of the multi-well plate and merge them into one row; Step 1.2: Merge by columns Take a certain volume from each well in each column of the compound combined in step 1.1 and combine them into one column. After two merging, each compound mixture obtained contains m*n compounds, where m is the number of merged rows and n is the number of merged columns, m is between 8 and 96, and n is between 5 and 10; 2) diluting and mixing the target protein and a group of compound mixtures obtained in step 1) with a reaction solution, incubating, and performing a desalting operation to separate the protein-compound complex; 3). Denaturing the protein using a protein denaturation method to release the lead compound in the complex, and freeze-drying it; 4) Detect the lead compound by thin layer chromatography: the freeze-dried sample in step 3) and the m*n compounds obtained in step 1) are dissolved in ethyl acetate and spotted on the same silica gel plate. After the spotting is completed, the ethyl acetate is completely volatilized, and the compounds are developed in sequence with a developing agent until the ratio shift value of the "lead compound" is between 0.2 and 0.8, thereby determining which column of the original compound mother plate the "lead compound" belongs to. Then, the m compounds in the column are dissolved in ethyl acetate and spotted and developed together with the lead compound in sequence, until the ratio shift value of the "lead compound" is between 0.2 and 0.8, thereby determining which row of the original compound mother plate the "lead compound" belongs to; 5) Determining the information of the hit compound according to the electronic file of the original compound master plate, wherein the electronic file of the original compound master plate is the information corresponding to the position of each compound in the storage container recorded when the compound library is established.

2. The method according to claim 1, wherein: In step 1), m is 16, n is 10, and 160 compounds are mixed by the following "two-step method": 160 compounds correspond to the total amount of compounds in two 96-well plates in the compound library, where each plate has 80 compounds. First, merge by row, use a 10-channel row gun to take 1 μL of compound from each well in each row of the two plates, and merge them into one row. At this time, there are 16 compounds in each well after merging; Then, the samples were merged by column, and 0.5 μL was taken from each well in each column of the compounds obtained in the previous step and merged into one column. At this point, after two mergers, a mixture of 160 compounds was obtained.

3. The method according to claim 1, wherein: In step 1), the multiple compounds are dissolved in dimethyl sulfoxide before mixing. After mixing, the dimethyl sulfoxide is removed using a freeze dryer, and a small amount of dimethyl sulfoxide is added to redissolve the compound sample. The volume of dimethyl sulfoxide added when redissolving the compound sample is between 1% and 12% of the total volume of the reaction solution in step 2, preferably 10% based on the tolerance of the target protein to dimethyl sulfoxide.

4. The method according to claim 1, wherein: In step 2), the target protein is a protein molecule that is closely related to the occurrence and development of the disease and has drug targeting significance, for example, it can be a full-length or truncated protein expressed by eukaryotic cells or prokaryotic cells.

5. The method according to claim 2, wherein: In step 4), the compound is developed in sequence using the following developing agents from #1 to #5 from low polarity to high polarity:

6. The method according to claim 5, wherein: In step 4), the freeze-dried sample and the 10 groups of 160 compounds after the first round of mixing in step 1 are dissolved in 5 μL of ethyl acetate and spotted on the same silica gel plate. After the spotting is completed, the ethyl acetate is completely evaporated, and the compounds are developed in sequence with 5 polar gradient developing agents from 1# to 5# respectively, until the ratio shift value of the "lead compound" is between 0.2 and 0.8, so as to determine which group the "lead compound" belongs to, that is, to determine which column of the original compound mother plate the compound belongs to. Then, the 16 compounds in the column are dissolved in ethyl acetate and spotted in sequence with the lead compound, and developed until the ratio shift value of the "lead compound" is between 0.2 and 0.8, so as to determine which group the "lead compound" belongs to, that is, to determine which row of the original compound mother plate the compound belongs to.

7. The method according to claim 1, wherein: In step 5), the information includes but is not limited to the CAS number, structure, molecular formula, and relative molecular mass of each compound.

8. A method for verifying the effect of a lead compound on the enzymatic activity reaction process of a protease, the method comprising the following steps: 2.1: Dilute the protease to be tested, the hit compound and the DMSO with the volume corresponding to the stock solution of the hit compound with the reaction solution to obtain a protease solution, a hit compound solution and a DMSO solution respectively, and mix the diluted protease solution and the hit compound solution as the experimental group; Corresponding to the volume of the experimental group, the diluted protease solution and the DMSO solution were mixed to form the NCC (no compound control) group; corresponding to the volume of the experimental group, the blank reaction solution and the diluted DMSO solution were mixed to form the NPC (no protein control) group; 2.2: Add the corresponding substrate diluted with the reaction solution to the mixed solution of the experimental group, NCC group and NPC group in step 2.1 to start the catalytic reaction; 2.3: heating the solution in step 2.2 to terminate the catalytic reaction; 2.4: Analyze the sample taken from step 2.3 by thin layer chromatography. Spot the sample taken from step 2.3 on a silica gel plate, develop it with a developing agent, and observe the difference in substrate consumption / product generation between the experimental group, NCC group, and NPC group to determine the inhibitory / stimulatory effect of the compound on the protease activity.

9. A method for verifying the effect of a lead compound on the binding of a protein to a small molecule substrate or a polypeptide, the method comprising the following steps: 3.1: The protein diluted with the reaction solution and the hit compound are mixed evenly, and incubated for a certain period of time as the experimental group, and a control group is set up at the same time. The difference between the control group and the experimental group is that the hit compound is not contained; 3.2: Add the small molecule substrate or polypeptide corresponding to the protein diluted with the reaction solution to the mixed solution of the experimental group and the control group obtained in step 3.1, respectively, and desalt after incubation for a certain period of time; 3.3: Denature the protein, take the effluent after desalting, and freeze-dry it; 3.4: Analyze the sample in step 3.3 by thin layer chromatography. Redissolve the sample in step 3.3 with solvent and spot it on the silica gel plate. Develop it with a developing agent and observe the changes in the recovery amount of substrate / peptide in the experimental group and the control group to determine the effect of the compound on the binding of protein with small molecule substrate or peptide.

10. The method according to claim 8 or 9, wherein in step 2.4 or in step 3.4, the following developing agents with different polarities from 1# to 5# are used in sequence for development:

Citation Information

Patent Citations

  • Protease screening methods and proteases identified thereby

    CA2791144A1

  • Method for verifying DNA encoded hit compound modified antibody in tandem manner

    CN112986575A

  • Method for generating, screening and dereplicating natural product libraries for the discovery of therapeutic agents

    US20030113797A1

  • Method for screening adulteration of fibrate Anti-hyperlipidemia chemicals in tea by combined method of high performance thin layer chromatography and bioluminescence

    US20210293833A1